The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.
While the initial purchase price was $600 million, the final amount could reach approximately $1.7 billion if certain milestones are met. V-Wave's VenturaInteratrial Shunt System for HFrEF has gained considerable interest in recent years, and Johnson & Johnson was an early investor in the technology back in 2016.
This study adds to growing evidence that e-cigarettes play a significant role in cardiovascular problems, similar to smoking. Researchers hope their work can help lead to new public health policies.
Patient outcomes, safety data and physician feedback were all used to rank the top children's hospitals for pediatric cardiology and heart surgery in the United States. Did your facility make the cut?
Early data suggest the drug, an oral lipoprotein (a) disruptor, could make a significant impact on patient care. AstraZeneca will pay $100 million upfront, with much more to follow if certain milestones are met.